Semaglutide Goes Generic: Big Pharma’s Moat Breaks
India's semaglutide moment has arrived. As Novo Nordisk's patent expires on March 20th, over fifty generic brands are poised to flood the market potentially slashing monthly costs from ₹10,000 to ₹3,500. But this is no ordinary generic wave. Semaglutide is a complex peptide, cold chains are unforgiving, and patient…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from The Morning Brief
See all episodes →
Similar episodes from other shows
More like The Morning Brief →
The price drop in weight-loss drugs Indian pharma can’t handle
Can India break this Pharma Monopoly?
Can India become the pharmacy for weight-loss drugs?
#041 Prices of Expensive Diabetes Drugs Are Falling And More Manufacturers Are Rushing In
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.